Our findings reveal a mechanism by which underlying hemostatic imbalances might increase the risk of thrombosis in the kidneys of human patients with CKD, and suggest PAR2 antagonism as a potential new therapeutic strategy for intervening in CKD progression. The gene discussed is F2RL1; the disease is chronic kidney disease.